Alba Therapeutics   Report issue

Contributed to NME For profit Phase 2
Founded: Baltimore MD United States (2004)
Status: Acquired by Cephalon (2011) → now Teva (2011)

Organization Overview

First Clinical Trial
2006
NCT00386490
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Alba Therapeutics Corp | Alba Therapeutics Inc

Active Ingredients

Drugs in Phase 2 Trials (2)

larazotide acetate (6 trials)

migalastat (galafold) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Celiac Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 2